Description :
Semaxanib is a quinolone derivative with potential antineoplastic activity. Semaxanib reversibly inhibits ATP binding to the tyrosine kinase domain of vascular endothelial growth factor receptor 2 (VEGFR2), which may inhibit VEGF-stimulated endothelial cell migration and proliferation and reduce the tumor microvasculature. This agent also inhibits the phosphorylation of the stem cell factor receptor tyrosine kinase c-kit, often expressed in acute myelogenous leukemia cells.
- Molecular Weight :238.28
- Melting Point :> 190ºC (dec.)
- Purity :98%
Molecular Formula :
C15H14N2O
Canonical SMILES :
CC1=CC(=C(N1)C=C2C3=CC=CC=C3NC2=O)C
InChI :
InChI=1S/C15H14N2O/c1-9-7-10(2)16-14(9)8-12-11-5-3-4-6-13(11)17-15(12)18/h3-8,16H,1-2H3,(H,17,18)/b12-8-
InChIKey :
WUWDLXZGHZSWQZ-WQLSENKSSA-N
Appearance :
Yellow to Orange Solid Powder
Application :
Angiogenesis Inhibitors
Synonyms :
SU5416; SU-5416; SU 5416; Sugen 5416; semoxind
More details are to be found
here
details